NADPHオキシダーゼ4治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:NADPH Oxidase 4 - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0404
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:65
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

NADPH Oxidase 4 – Pipeline Review, H2 2019
Summary

According to the recently published report ‘NADPH Oxidase 4 – Pipeline Review, H2 2019′; NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) pipeline Target constitutes close to 6 molecules.

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) – NADPH oxidase 4 is an enzyme belonging to NOX family of NADPH oxidases. NADPH Oxidase 4 is localized to non-phagocytic cells where it acts as an oxygen sensor and catalyzes the reduction of molecular oxygen to various reactive oxygen species. So formed ROS have been implicated in numerous biological functions including signal transduction, cell differentiation and tumor cell growth.

The report ‘NADPH Oxidase 4 – Pipeline Review, H2 2019′ outlays comprehensive information on the NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 4 respectively. Report covers products from therapy areas Cardiovascular, Metabolic Disorders, Respiratory, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Musculoskeletal Disorders, Oncology and Toxicology which include indications Idiopathic Pulmonary Fibrosis, Acute Ischemic Stroke, Atherosclerosis, Chlorine Poisoning, Diabetic Complications, Diabetic Nephropathy, Fibrosis, Gastrointestinal Radiation Toxicity, Ischemia Reperfusion Injury, Kidney Fibrosis, Liver Fibrosis, Mustard Gas (Sulfur Mustard) Poisoning, Nerve Gas Poisoning, Non-Alcoholic Steatohepatitis (NASH), Portal Hypertension, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Progressive Supranuclear Palsy, Prostate Cancer, Pulmonary Radiation Toxicity, Systemic Sclerosis (Scleroderma) and Type 2 Diabetes.

Scope

- The report provides a snapshot of the global therapeutic landscape for NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.)
- The report reviews NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics and enlists all their major and minor projects
- The report assesses NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) – Overview
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) – Companies Involved in Therapeutics Development
GenKyoTex SA
Glucox Biotech AB
New Amsterdam Sciences Inc
OliPass Corporation
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) – Drug Profiles
Antisense Oligonucleotides to Inhibit NOX4 for Fibrosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAS-150 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setanaxib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NOX-4 for Acute Ischemic Stroke – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NOX-4 for Diabetes – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NOX4 and NOX2 for Ischemia Reperfusion Injury – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) – Dormant Products
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) – Discontinued Products
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) – Product Development Milestones
Featured News & Press Releases
Dec 03, 2019: Genkyotex reports progress of Setanaxib Phase 2 investigator initiated trials
Jul 25, 2019: Genkyotex announces positive post-hoc analysis of PBC phase 2 trial and reports cash position at June 30, 2019
Jul 24, 2019: Genkyotex conference call for post-hoc analysis of Setanaxib (GKT831) PBC Ph2 trial and business update
Jul 22, 2019: The WHO recognizes NOX inhibitors as new therapeutic class and approves setanaxib for GKT831
Jul 18, 2019: Genkyotex to launch Phase II pulmonary fibrosis trial in US
Jul 01, 2019: Genkyotex’s GKT831 prevents multiple complications of portal hypertension in preclinical model
Jun 24, 2019: Genkyotex announces positive final results of GKT831 trial in PBC
May 23, 2019: Genkyotex invites shareholders to Annual General Meeting on June 13, 2019
May 21, 2019: Preclinical study of GKT831 shows rapid regression of cholestatic fibrosis in model of advanced liver fibrosis
May 02, 2019: Genkyotex reports mixed efficacy Phase II data for PBC drug
Apr 08, 2019: Genkyotex to present updated interim results from Phase 2 trial of GKT831 in Primary Biliary Cholongitis at 2019 EASL International Liver Congress (ILC)
Mar 11, 2019: Genkyotex announces completion of 24-week treatment period of its phase 2 yrial with GKT831 in primary biliary cholangitis
Feb 11, 2019: Genkyotex Announces Award of Grant from Cancer Research UK to Academic Partner to Further Develop NOX Research in Oncology
Jan 25, 2019: Genkyotex provides update on its primary biliary cholangitis drug candidate GKT831
Dec 19, 2018: Genkyotex announces an extraordinary shareholders meeting to be held on January 24, 2019 at 10 am and confirms the key development milestone for GKT831 in PBC
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by GenKyoTex SA, H2 2019
Pipeline by Glucox Biotech AB, H2 2019
Pipeline by New Amsterdam Sciences Inc, H2 2019
Pipeline by OliPass Corporation, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

【掲載企業】

GenKyoTex SA
Glucox Biotech AB
New Amsterdam Sciences Inc
OliPass Corporation

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[NADPHオキシダーゼ4治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆